Concepedia

Author

Hirotake Shiraiwa

Chugai Pharma (United States)ORCID

Also Known As

H Shiraiwa, Hirotake Shiraiwa

38

Publications

419

Citations

7

H-Index

15

Concepts

All Affiliations

Chugai Pharma (United States)
HS

About

Hirotake Shiraiwa is an author at Chugai Pharma (United States) specializing in immunology, immunotherapy, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

116

2

Engineering

1

1

51

3

Biomolecular Engineering

1

1

51

4

Cell Biology

1

1

65

5

Cellular Therapies

1

1

65

Hirotake Shiraiwa

×

7

Publications

401

Citations

7

H-Index

YearCitations

An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors

Takahiro Ishiguro, Yuji Sano, Shunichiro Komatsu,

Science Translational Medicine

2017

195

A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients

Teruaki Sekine, Hirotake Shiraiwa, Takamasa Yamazaki,

Biomedicine & Pharmacotherapy

1993

65

Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974

Hirotake Shiraiwa, Atsushi Narita, Mika Kamata‐Sakurai,

Methods

2018

51

A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state

Yuri Teranishi-Ikawa, Tetsuhiro Soeda, Hikaru Koga,

Journal of Thrombosis and Haemostasis

2023

34

A defucosylated anti‐CD317 antibody exhibited enhanced antibody‐dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients

Takahiro Ishiguro, Shigeto Kawai, Kiyoshi Habu,

Cancer Science

2010

22

Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer

Hirofumi Mikami, Shu Feng, Yutaka Matsuda,

Cancer Immunology Research

2024

19

Efficient production of bispecific antibody by FAST-Ig <sup>TM</sup> and its application to NXT007 for the treatment of hemophilia A

Hikaru Koga, Takashi Yamano, Juan Felipe Betancur,

mAbs

2023

15

Page 1